Clinical Trial

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2026 (before its estimated February 13, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects
Trial Details
NCT Number NCT07377175
Lead Sponsor China National Biotec Group Company Limited
Collaborators: Beijing Institute of Biological Products Co Ltd., Shulan (Hangzhou) Hospital
Conditions Smallpox, Cowpox, Monkeypox, Poxvirus Infection
Enrollment 76 participants
Start Date 2025-08-28
Primary Completion 2026-02-13 (estimated)
Study Completion 2026-02-13 (estimated)
Updated on ClinicalTrials.gov 2026-01-29